Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers.
2006 Jan 23
Journal Article
Authors:
Cebere, I.;
Dorrell, L.;
McShane, H.;
Simmons, A.;
McCormack, S.;
Schmidt, C.;
Smith, C.;
Brooks, M.;
Roberts, J.E.;
Darwin, S.C.;
Fast, P.E.;
Conlon, C.;
Rowland-Jones, S.;
McMichael, A.J.;
Hanke, T.
Secondary:
Vaccine
Volume:
24
Pagination:
417-25
Issue:
4
PMID:
16176847
DOI:
10.1016/j.vaccine.2005.08.041
Keywords:
AIDS Vaccines; Drug Design; Genetic Vectors; HIV Infections; HIV-1; Human Experimentation; Humans; immunization; Immunization Schedule; Immunization, Secondary; Single-Blind Method; Vaccines, DNA; Vaccinia virus
Abstract:
DNA- and modified virus Ankara (MVA)-vectored candidate vaccines expressing human immunodeficiency virus type 1 (HIV-1) clade A-derived p24/p17 gag fused to a string of HLA class I epitopes, called HIVA, were tested in phase I trials in healthy, HIV-1/2-uninfected adults in Oxford, United Kingdom. Eighteen volunteers were vaccinated with pTHr.HIVA DNA (IAVI-001) alone, 8 volunteers received MVA.HIVA (IAVI-003) alone and 9 volunteers from study IAVI-001 were boosted with MVA.HIVA 9-14 months after DNA priming (IAVI-005). Immunogenicity results observed in these trials was published previously [Mwau M, Cebere I, Sutton J, Chikoti P, Winstone N, Wee EG-T, et al. An HIV-1 clade A vaccine in clinical trials: stimulation of HIV-specific T cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 2004;85:911-9]. Here, we report on the safety of the two vaccines and the vaccine regimes. Overall, both candidate vaccines were safe and well tolerated. There were no reported vaccine-related adverse events over the 6-month period of the study and up to 2 years after the last vaccination. There were no moderate or severe local symptoms recorded after the pTHr.HIVA DNA intramuscular administration. Almost all participants experienced local reactogenicity events such as redness and induration after MVA.HIVA intradermal injection. Thus, the results from these initial small phase I trials administering the pTHr.HIVA DNA and MVA.HIVA vaccines either alone or in a prime-boost regime to healthy HIV-1/2-negative adults indicated that the vaccines were safe and warranted further testing of this approach in larger phase I/II studies.
